- Home
- SLNO
as 11-20-2024 4:00pm EST
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 1.9B | IPO Year: | 2014 |
| Target Price: | $69.86 | AVG Volume (30 days): | 505.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.38 - $59.75 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Oct 1 '24 | Sell | $49.79 | 8,077 | $399,241.39 | 119,172 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Oct 1 '24 | Sell | $49.79 | 21,633 | $1,069,306.22 | 719,553 | |
| Yen Kristen | SLNO | SEE REMARKS | Oct 1 '24 | Sell | $49.79 | 3,108 | $153,626.63 | 81,465 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Oct 1 '24 | Sell | $49.79 | 3,108 | $153,626.63 | 108,932 | |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Aug 28 '24 | Sell | $47.55 | 13,531 | $641,782.70 | 119,172 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Aug 28 '24 | Sell | $47.55 | 115,004 | $5,454,707.25 | 719,553 | |
| Yen Kristen | SLNO | SEE REMARKS | Aug 28 '24 | Sell | $47.55 | 10,705 | $507,744.55 | 81,465 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Aug 28 '24 | Sell | $47.55 | 10,705 | $507,744.55 | 108,932 | |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Aug 27 '24 | Sell | $47.77 | 1,025,000 | $49,210,750.00 | 6,816,851 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
Simply Wall St.
9 days ago
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
GlobeNewswire
15 days ago
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
24 days ago
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
Barrons.com
a month ago
Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors
GlobeNewswire
a month ago
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
Barrons.com
a month ago
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors
Insider Monkey
a month ago
Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.